Table 1 Baseline clinical characteristics of patients in the training cohort.
Variable | Recurrence | No | |
|---|---|---|---|
Age, years | Median (range) | 59 (52–68) | 49 (29–69) |
mean ± SD | 59.7 ± 4.5 | 50.7 ± 9.4 | |
Gender, n (%) | male | 26 (25.7) | 57 (56.4) |
female | 4 (4.0) | 14 (13.9) | |
Cirrhosis, n (%) | yes | 27 (26.7) | 69 (68.3) |
no | 3 (3.0) | 2 (2.0) | |
Etiology, n (%) | HBV infection | 29 (28.7) | 60 (59.4) |
HCV infection | 1 (1.0) | 5 (5.0) | |
alcohol abuse | 0 (0) | 2 (2.0) | |
Budd-Chiari syndrome | 0 (0) | 1 (1.0) | |
schistosome infection | 0 (0) | 1 (1.0) | |
HBV infection + alcohol abuse | 0 (0) | 1 (1.0) | |
HBV + HEV infection | 0 (0) | 1 (1.0) | |
HBV + HCV infection | 0 (0) | 0 (0) | |
AIH | 0 (0) | 0 (0) | |
Child-Pugh score | A | 20 (19.8) | 41 (40.6) |
B | 8 (8.0) | 26 (25.8) | |
C | 2 (2.0) | 4 (4.0) | |
MELD score | Median (range) | 7 (3–30) | 8 (1–25) |
AFP level | ≤20 ng/mL | 5 (5.0) | 34 (33.7) |
>20 ng/ mL, ≤200 ng/mL | 3 (3.0) | 16 (15.8) | |
>200 ng/ mL, ≤400 ng/mL | 3 (3.0) | 8 (7.9) | |
>400 ng/ mL | 19 (18.8) | 13 (12.9) | |
CK19/GPC3 sub-typing, n (%) | CK19+/GPC3+ | 8 (7.9) | 3 (3.0) |
CK19−/GPC3+ | 21 (20.8) | 35 (34.7) | |
CK19−/GPC3− | 1 (1.0) | 33 (32.7) | |
Histological grading, n (%) | poorly | 16 (15.8) | 19 (18.8) |
moderately | 13 (12.9) | 35 (34.7) | |
well | 1 (1.0) | 17 (16.8) | |
Macroscopic vascular invasion, n (%) | yes | 11 (10.9) | 6 (5.9) |
no | 19 (18.8) | 65 (64.4) | |
Microscopic vascular invasion, n (%) | yes | 23 (22.8) | 29 (28.7) |
no | 7 (6.9) | 42 (41.6) | |
Tumor diameter, n (%) | ≤3 cm | 9 (8.9) | 54 (53.5) |
>3 cm, ≤5 cm | 6 (5.9) | 11 (10.9) | |
>5 cm | 15 (14.9) | 6 (5.9) | |
Milan criteria, n (%) | within | 15 (14.9) | 65 (64.4) |
beyond | 15 (14.9) | 6 (5.9) | |
UCSF criteria, n (%) | within | 20 (19.8) | 68 (67.3) |
beyond | 10 (9.9) | 3 (3.0) | |
Fudan criteria, n (%) | within | 24 (23.8) | 70 (69.3) |
beyond | 6 (5.9) | 1 (1.0) | |
Hangzhou criteria, n (%) | within | 25 (24.8) | 69 (68.3) |
beyond | 5 (5.0) | 2 (2.0) |
